Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 151

1.

Malignancy concerns of topical calcineurin inhibitors for atopic dermatitis: facts and controversies.

Thaçi D, Salgo R.

Clin Dermatol. 2010 Jan-Feb;28(1):52-6. doi: 10.1016/j.clindermatol.2009.04.001. Review.

PMID:
20082951
[PubMed - indexed for MEDLINE]
2.

Safety and efficacy of topical calcineurin inhibitors in the treatment of childhood atopic dermatitis.

Breuer K, Werfel T, Kapp A.

Am J Clin Dermatol. 2005;6(2):65-77. Review.

PMID:
15799678
[PubMed - indexed for MEDLINE]
3.

The topical calcineurin inhibitor pimecrolimus in atopic dermatitis: a safety update.

Thaçi D, Salgo R.

Acta Dermatovenerol Alp Pannonica Adriat. 2007 Jun;16(2):58, 60-62. Review.

PMID:
17992459
[PubMed - indexed for MEDLINE]
Free Article
4.

[Practice experience with topical calcineurin inhibitors].

Lübbe J.

Hautarzt. 2003 May;54(5):432-9. Epub 2003 Apr 1. Review. German.

PMID:
12719863
[PubMed - indexed for MEDLINE]
5.

Cancer concerns with topical immunomodulators in atopic dermatitis: overview of data and recommendations to clinicians.

Patel TS, Greer SC, Skinner RB Jr.

Am J Clin Dermatol. 2007;8(4):189-94. Review.

PMID:
17645374
[PubMed - indexed for MEDLINE]
6.

Topical calcineurin inhibitors in the treatment of atopic dermatitis - an update on safety issues.

Czarnecka-Operacz M, Jenerowicz D.

J Dtsch Dermatol Ges. 2012 Mar;10(3):167-72. doi: 10.1111/j.1610-0387.2011.07791.x. Epub 2011 Oct 6. Review.

PMID:
21974750
[PubMed - indexed for MEDLINE]
Free Article
7.

The use of topical calcineurin inhibitors in dermatology: safety concerns. Report of the American Academy of Dermatology Association Task Force.

Berger TG, Duvic M, Van Voorhees AS, VanBeek MJ, Frieden IJ; American Academy of Dermatology Association Task Force.

J Am Acad Dermatol. 2006 May;54(5):818-23. Review. No abstract available. Erratum in: J Am Acad Dermatol. 2006 Aug;55(2):271. VanBeek, Marta J [added].

PMID:
16635663
[PubMed - indexed for MEDLINE]
8.

Safety of topical calcineurin inhibitors for the treatment of atopic dermatitis.

Munzenberger PJ, Montejo JM.

Pharmacotherapy. 2007 Jul;27(7):1020-8. Review.

PMID:
17594208
[PubMed - indexed for MEDLINE]
9.

Topical treatments with pimecrolimus, tacrolimus and medium- to high-potency corticosteroids, and risk of lymphoma.

Schneeweiss S, Doherty M, Zhu S, Funch D, Schlienger RG, Fernandez-Vidaurre C, Seeger JD.

Dermatology. 2009;219(1):7-21. doi: 10.1159/000209289. Epub 2009 Mar 17.

PMID:
19293564
[PubMed - indexed for MEDLINE]
10.

[Topical immune modulation and risk of cancer].

Deleuran M, Zachariae C, Thestrup-Pedersen K.

Ugeskr Laeger. 2009 Aug 24;171(35):2468-71. Review. Danish.

PMID:
19732533
[PubMed - indexed for MEDLINE]
11.

The role of topical calcineurin inhibitors in atopic dermatitis.

Alomar A, Berth-Jones J, Bos JD, Giannetti A, Reitamo S, Ruzicka T, Stalder JF, Thestrup-Pedersen K; European Working Group on Atopic Dermatitis.

Br J Dermatol. 2004 Dec;151 Suppl 70 Dec 2004:3-27. Review.

PMID:
15548171
[PubMed - indexed for MEDLINE]
12.

Safety of topical calcineurin inhibitors in atopic dermatitis: evaluation of the evidence.

Spergel JM, Leung DY.

Curr Allergy Asthma Rep. 2006 Jul;6(4):270-4. Review.

PMID:
16822378
[PubMed - indexed for MEDLINE]
13.

[The treatment of atopic dermatitis in adults with topical calcineurin inhibitors].

Meurer M, Wozel G.

Hautarzt. 2003 May;54(5):424-31. Epub 2003 Apr 4. German.

PMID:
12719862
[PubMed - indexed for MEDLINE]
14.

Long-term safety of tacrolimus ointment in atopic dermatitis.

Remitz A, Reitamo S.

Expert Opin Drug Saf. 2009 Jul;8(4):501-6. doi: 10.1517/14740330902969441 . Review.

PMID:
19435404
[PubMed - indexed for MEDLINE]
15.

Association between exposure to topical tacrolimus or pimecrolimus and cancers.

Hui RL, Lide W, Chan J, Schottinger J, Yoshinaga M, Millares M.

Ann Pharmacother. 2009 Dec;43(12):1956-63. doi: 10.1345/aph.1M278. Epub 2009 Nov 10.

PMID:
19903860
[PubMed - indexed for MEDLINE]
16.

[Long term management of childhood atopic dermatitis with calcineurin inhibitors].

Thaçi D.

Hautarzt. 2003 May;54(5):418-23. Epub 2003 Apr 4. German.

PMID:
12719861
[PubMed - indexed for MEDLINE]
17.

[Calcineurin inhibitors in treatment of atopic dermatitis. Topical corticoids now only in severe outbreaks? ].

[No authors listed]

MMW Fortschr Med. 2003 Jul 24;145(29-30):62. German. No abstract available.

PMID:
12958787
[PubMed - indexed for MEDLINE]
18.

Comparative effectiveness of topical calcineurin inhibitors in adult patients with atopic dermatitis.

Frankel HC, Qureshi AA.

Am J Clin Dermatol. 2012 Apr 1;13(2):113-23. doi: 10.2165/11597780-000000000-00000. Review.

PMID:
22263704
[PubMed - indexed for MEDLINE]
19.

Black box warning for topical calcineurin inhibitors and the death of common sense.

Fleischer AB Jr.

Dermatol Online J. 2006 Oct 31;12(6):2.

PMID:
17083882
[PubMed - indexed for MEDLINE]
20.

[Topical pimecrolimus and tacrolimus and the risk of cancer].

Sánchez-Pérez J.

Actas Dermosifiliogr. 2007 Jun;98(5):312-7. Review. Spanish.

PMID:
17555673
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk